Hint mode is switched on Switch off
For swift navigation between sections

Ligand Pharmaceuticals
LEI 5493008K7TB0IKP37H79

PDF download

Choose all Reset all
Download Cancel
Organization name
Ligand Pharmaceuticals, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
1,085 mln USD
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company’s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer’s VFEND IV and Baxter International’s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It’s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. 

Awards

News

14/07/2026 Ligand Pharmaceuticals: Entry Into A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Creation Of A Direct Financial Obligation Or An Obligation Under An, Regulation Fd Disclosure, Financial Statements And Exhibits
25/06/2026 New issue: Ligand Pharmaceuticals issued bonds in the amount of USD 625 mln maturing in 2031
25/06/2026 Ligand Pharmaceuticals: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An, Unregistered Sale Of Equity Securities, Other Events, Financial Statements And Exhibits
23/06/2026 Upcoming Issue: Pharmaceuticals
05/06/2026 Pharmaceuticals: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Submission Of Matters To A Vote Of Security Holders
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    5493008K7TB0IKP37H79
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0000886163
  • EIN
    77-0160744
Registration is required to get access.